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INTRODUCTION
 Myofascial pain syndrome (MPS) is a common 
clinical condition of muscle pain. In the United 
States, MPS is estimated to affect approximately 3% 
of the general population1). It was diagnosed in 30% 
of patients with pain complaints at a university 
general internal medicine department2), and in 85% 
of patients at a pain rehabilitation referral center3). 
MPS is characterized by: 1) chronic muscle pain, 
2) palpation of taut bands in painful muscles, and 
3) exquisite tenderness spots in taut bands which 
evoke referred pain when physically pressed4).
 Various local therapies exist for MPS such as 
local anesthetic injection, dry needling, laser 
acupuncture, physiotherapy, and massage. In studies 
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ABSTRACT
 Myofascial pain syndrome (MPS) is a common clinical condition of muscle pain. Previous studies 
indicated that local injection of physiological saline (PS) into a muscle is equal to or more effective than a 
local anesthetic for MPS. We performed 2 randomized, double-blinded trials of interfascial injection under 
ultrasonography for outpatients with MPS over 3 months to assess the effects of PS (pH 6.0), 0.5% 
mepivacaine hydrochloride (MH) (pH 6.0), and bicarbonate Ringer’s solution (BRS) (pH 7.4), and to 
elucidate their action mechanisms. Maximum pain related to motion, time of pain relief, and pain related 
to injection (intensity and duration) were measured up to 72 hrs. The first trial showed that PS decreased 
maximum pain related to motion compared to MH (p < 0.05), although it increased pain related to 
injection compared to MH (p < 0.05). The second trial showed that BRS exhibited as much efficacy in 
relieving maximum pain related to motion as PS (p = 0.33), but decreased pain related to injection 
compared to PS (p < 0.05). In conclusion, the interfascial injection of PS has a greater analgesic effect on 
MPS but produced stronger pain related to injection compared to MH. BRS is equivalent to PS in 
analgesic effect and produced less pain related to injection compared to PS. These results indicate that 
BRS is the appropriate solution for an interfascial injection to treat MPS, and that the action mechanisms 
are not related to the pain intensity associated with the injections or the pharmacological anesthetic effect.
Key word: acupuncture, chronic pain, myofascia, trigger points, ultrasound
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Abbreviations: BRS, bicarbonate Ringer’s solution;ISM, infraspinatus muscle;LSM, levator scapulae muscle;MH, 
mepivacaine hydrochloride;MPS, myofascial pain syndrome;NRS, numeric rating scale;PS, physiological saline;ROM, 
range of motion;SM, middle scalene muscle;TM, upper parts of the trapezius muscle;TSM, cervical, thoracic and 
lumbar transversospinal muscle;VAS, visual analogue scale 
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using local anesthetic injection, physiological saline 
(PS) has traditionally been used for placebo control. 
However, a previous study showed that a local 
injection (into a muscle tissue) of PS for MPS patients 
was equally or more effective than an injection of 0.5% 
mepivacaine hydrochloride (MH) (local anesthetic)5). 
Pain related to injection of PS tends to be greater 
than that of a local anesthetic. Some studies indicated 
that the stronger the intensity of pain related to 
injection, the greater its analgesic effect, but these 
results are controversial6)-8). The Systematic reviews in 
the Cochrane database showed that adjusting the pH 
of a solution to a level closer to the physiologic pH 
7.4 reduces pain related to injection9). Accordingly, 
we expected that the local injection of bicarbonated 
Ringer’s solution (BRS) (extracellular fluid similar 
to blood plasma, pH 7.4) would be far less painful 
than PS, but as effective as PS. 
 Interfascial injection with a local anesthetic has 
been used as a compartment block for nerve block 
anesthesia10)-14). The interfascial block of a local 
anesthetic was suggested to be effective in treating 
MPS patients. The fluid injected into the interfascial 
space of cadavers under ultrasonography has been 
confirmed by anatomical dissection15). Dense 
innervation of sensory fibers, including presumably 
nociceptive fibers, on the outer layer of thoracolumbar 
fascia was reported16). Approaching the outside of the 
myofascia (epimysium) might be more effective than 
approaching the inside (muscle tissue). However, 
there are no prospective studies about the effect of 
interfascial injection in MPS patients.
 Interfascial injection of PS or BRS is expected to 
reduce complications of local anesthetics. We 
performed interfascial injection under ultrasonography 
which enabled us to determine the injection site and 
the injected solution in the interfascial space. We 
compared the efficacy and safety of the interfascial 
injection of PS, MH and BRS for MPS patients, and 
attempted to elucidate the possible action mechanisms 
of interfascial injection. 
METHODS
 Full ethical approval was granted for the study 
(Medical Ethics Committee of Kanazawa University). 
The study was registered in the University Hospital 
M e d i c a l  I n f o r m a t i o n  N e t w o r k  i n  J a p a n 
(UMIN000009701). It was a prospective, randomized, 
active-controlled, double-blinded study performed at 
an outpatient pain clinic in Japan, divided into 2 
parts; first, we compared PS (pH 6.0) and MH (pH 
6.0)(as active controls) from January 26th to February 
2nd 2013, and second, we compared BRS (pH 7.4) and 
PS (pH 6.0)(as active controls) from March 11th to 16th 
2013. The protocols in the first and second trials were 
completely the same except for the solutions (MH or 
BRS) used.
Patients
 Recruitment ran from January to March 2013. 
Patients treated at the Kimura Pain Clinic (Maebashi, 
Japan) were invited to participate. Written informed 
consent was given by all patients before enrolment in 
the studies. A physician of the clinic preselected the 
patients and informed them about the eligibility and 
exclusion criteria. Patients who were eligible and 
willing to participate in the study were then assessed 
by an independent examiner including a detailed 
physical examination and collection of baseline data. 
 The eligibility criteria were MPS of specific 
muscles for at least 3 months. MPS criteria were the 
following: 1) regional muscle pain, 2) palpation of taut 
bands in painful muscles, 3) exquisite tenderness spots 
(myofascial trigger points) in the taut bands, 4) patient’s 
recognition of pain evoked by physical pressing on a 
myofascial trigger point, and 5) limitation of the 
passive range of motion (ROM) due to muscle pain4). 
The specific muscles investigated in our study were 
the following: cervical, thoracic and lumbar 
transversospinal muscle (TSM), levator scapulae 
muscle (LSM), middle scalene muscle (SM), upper 
parts of the trapezius muscle (TM), and infraspinatus 
muscle (ISM). The exclusion criteria were the 
following: taking anti-thrombotic drugs or anti-
coagulant drugs, history of bleeding disorders, 
presence of cancer, history of spinal or shoulder 
surgery, presence of a local or systemic infection, 
acute trauma (within a week), allergy to anesthetic 
agents, and extreme fear of needles1). In addition, we 
excluded the patients who disagreed to stop any other 
usual treatments (e.g., physical therapy, acupuncture, 
massage, or per-request medications) until their 
participating trial finished. Regular medications were 
allowed to take.
Clinical trial endpoints 
 The endpoints were the same before and after the 
study was started. Here are our endpoints for the 
adapted final research protocol that was accepted by 
the Ethical Committee at Kanazawa University. 
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 The primary endpoint was the change over time 
in the maximum pain related to motion which had 
been used in the previous study18). Patients were 
asked to move their MPS-affected muscle in the 
most pain-inducing direction and to score the pain 
intensity on a numeric rating scale (NRS) of 0 to 10 
with 0 equaling “no pain” and 10 equaling “the worst 
pain possible.” The direction we measured was for 
the maximum extended positions of each muscle 
(TSM, LSM, SM, TM, and ISM). The respective 
change in pain intensity was recorded over time 
(before the intervention, 5, 15, and 30 min after, and 
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 48 and 72 hr 
after the injection). The pain intensities were 
recorded in the clinic until 2 hrs after the injection, 
and from 3 to 72 hr afterward were recorded by the 
patients at home. Patients did not need to record 
times when they forgot to keep track or during sleep.
 We defined 4 secondary endpoints: 1) The time of 
pain relief was defined as the duration in which the 
patient felt efficacy from the intervention. Patients 
recorded if they felt efficacy or not at the same time 
that the maximum pain related to intensity was 
recorded. 2) The intensity and duration of pain 
associated with injection. Pain intensity was recorded 
by NRS. Pain duration was recorded as the time it 
lasted after the injection. 3) Changes in the passive 
ROM of the MPS muscle after the injection. Before 
the injection, an examiner examined the passive 
ROM of the MPS-affected muscle at maximum 
extension. Thirty minutes after the injection, the 
examiner examined again if the passive ROM 
improved or not (i.e. Yes or No). 4) Adverse events. 
We recorded any uncomfortable physiological 
symptoms and signs (e.g., paralysis, hypoesthesia, 
nausea, vasovagal reflex, hypotension, allergic 




 After basel ine assessment, pat ients were 
randomly assigned by a roll of the dice to either the 
PS group or MH group in the first trial, and to the PS 
group or BRS group in the second trial. The 
examiners were all blinded, as mentioned below. 
 The specific steps of randomization and allocation 
were as follows: 1) Physician A preselected the patients 
and informed them about the eligibility and exclusion 
criteria. 2) Physician B assessed the participants who 
were eligible and willing to participate in the trial. This 
assessment included a detailed physical examination 
and collection of baseline data. 3) Nurse A rolled the 
dice for the randomization to the first patient every 
day, assigning one group even numbers and the other 
group odd numbers on the cast of the dice. The first 
patient was assigned to the one group, the second 
patient was assigned to the other group, the third to 
the one group, and so on. 4) Nurse B prepared the 
medicinal solutions (PS, MH, or BRS), and tools 
(syringes and boxes were of the same shape, and 
every solution was transparent, colorless and 
odorless). 5) Nurse A handed over a randomized 
syringe to physician B. 6) Physician B performed the 
interfascial injection under ultrasonography. 7) Nurse 
C (estimator of the outcomes) recorded the outcome 
measurements. 
Injection points and injected volume
 The injected points were either the most painful 
point on the margins of the MPS-affected muscle 
(inter-muscles) or the point between the muscle and 
the bone. We selected the 4 following spaces and 
injection volumes: between TSM and the vertebra 
when the affected muscle was TSM (injected volume: 
10 ml); between LSM and SM when the affected 
muscle was LSM and SM (5 ml); the space between 
LSM and TM when the MPS-affected muscle was 
LSM and TM (5 ml); between ISM and the scapula 
when the affected muscle was ISM (7 ml).  
Protoco l o f in ter fasc ia l in jec t ion under 
ultrasonography
 We defined “interfascial space” as the space outside 
of a muscle or a tendon (i.e., subcutaneous space, the 
space between epimysiums, the space between the 
periosteum and epimysium, and the space around 
tendons). Each patient was given a single injection of 
a randomized solution. The patients’ positions during 
the injection were supine, lateral or prone, for 
comfort. We performed the injections with 23-gauge 
needle (outer diameter: 0.60 mm, length: 60 mm) for 
the space between TSM and the vertebra, and with 
27-gauge needles (outer diameter: 0.40 mm, length: 
19 mm or 38 mm) for the others. 
 We performed interfascial injection under 
ultrasonography. The representative injected 
solutions between the LSM and TM were shown in 
Fig. 1a. To identify the interfascial space between 
TSM and the vertebra, we also applied the so-called 
“loss-of-resistance technique,”17) which were 
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generally performed to identify the epidural space 
during epidural puncture under ultrasonography 
(Noblus by Hitachi Aloka Medical, Co., Ltd., Tokyo, 
Japan. Authorization number: 224ABBZX-00092000); 
1) A needle with air in the syringe was inserted into 
the skin. 2) By slowly introducing the needle into the 
interfascial space with intermittent or continuous 
pressure on plunger of the syringe, we confirmed the 
interfascial space by checking air spreading into the 
space under ultrasonography and/or the feeling of 
sudden loss of the pressure on plunger of the syringe. 
3) We injected the randomized solution at the 
designated site under ultrasonography. The injected 
solutions between the TSM and the vertebra were 
shown in Fig. 1b. 
Protocol after interfascial injection
 We used no other treatment (e.g., no physiological 
therapy, acupuncture, massage, hot pack, nor additional 
medications). We kept the patients at rest in bed until 
30 minutes after the injection, and then checked their 
blood pressure and looked for any adverse events. We 
asked patients for their cooperation in not using any 
other treatments until their recordings were finished, 
but they were allowed to receive any other treatment 
they wished. If they received any other treatments, 
however, we would exclude them from the study. 
We allowed the patients to ask us about the present 
study and their conditions by snail mail, e-mail and 
telephone. The patients were asked to turn in their 
finished records to the clinic by hand or mail after 
the protocol.
Statistics
 For analyses of change in maximum pain related 
to motion (NRS) of primary endpoint, we tested the 
2-way repeated measure ANOVA, followed by 
Holm-Sidak multiple comparison tests, if warranted. 
The data were expressed as mean ? SEM. We tested 
our hypotheses on quantitative data about the time of 
pain relief, pain related to interfascial injection, 
adverse events, and passive ROM with Mann-
Whitney’s U test. A P value of < 0.05 was considered 
significant. All calculations were carried out with the 
SigmaPlot 12.5 statistical software (Systat Software, 
Inc. USA). 
 Sample size calculation was performed to primary 
endpoint before the studies started. Our intention was 
to analyze at least 18 patients per group, which if given 
a standard deviation of 1.818), would have provided 
90% power at the 5% significance level to detect a 
2-point difference in change in maximum pain related 
to motion. We estimated a dropout rate of 10% and 
therefore aimed to recruit 40 patients for each trial. 
Forty-one patients participated in the first trial as well 
as the second. The size was decided upon considering 
the minimum number of participants needed to detect 




 In the first trial (Fig. 2a), we included 41 patients; 
20 patients were randomly assigned to the PS group 
and 21 patients to the MH group. In the second trial 
(Fig. 2b), we also included 41 patients; 21 patients 
were randomly assigned to the BRS group and 20 to 
the PS group. No patients were lost to follow-up in 
either trial. Six patients were overlapped between the 
first trial and the second. The groups of patients in 
both trials had no statistically significant difference 
in demographic (e.g., mean age, woman sex, mean 
d isease dura t ion , drugs taken) and d isease 
characteristics (e.g., mean pain intensity of MPS 
affected muscle before the injection) (Table 1).
Fig. 1. Injected solutions between inter fascial spaces under 
ultrasonography. 
 (a) Injected solution between the levator scapulae muscle 
(LSM) and the trapezius muscle (TM). (b) Injected solution 
between the transversospinal muscle (TSM) and the vertebra 
after the ?Loss of resistance method.?
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Fig. 2. Flowchart diagram according to CONSORT statement for the report of randomized controlled trials. (a) Participant flow chart in the 
first trial. (b) Participant flow chart in the second trial.
Mean (SD) age (years)
Woman sex (No (%))
Mean (SD) disease duration (years)
Mean (SEM) pain intensity before   injection (NRS) 
Injection points (No (%)):
　between TSM and vertebra
　between LSM and SM 
　between LSM and TM 
　between ISM and scapula
Fibromyalgia (No (%)) a)
Drugs taken (total)(No (%)) b)
　non-steroidal anti-inflammatory drugs (No (%))
　psychotropic drugs (No (%))

























































PS: physiological saline. MH: 0.5% mepivacaine hydrochloride. BRS: bicarbonate Ringer’s solution. TSM: transversospinal muscle. LSM: 
levator scapulae muscle. SM: middle scalene muscle. TM: upper parts of the trapezius muscle. ISM: infraspinatus muscle.
a)Diagnostic criteria of fibromyalgia (American College of Rheumatology. “FAST FACTSa”) are as follows. There are 18 designated possible 
tender points. The patient must feel pain at 11 or more of these points for fibromyalgia to be considered. b)The detail includes overlap.
Table 1. Baseline characteristics of the first and second trial
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Confirmation of interfascial injection under 
ultrasonography 
 We checked the injected fluid in the interfascial 
space by ul t rasonography. Ultrasonography 
examination revealed that we could successfully 
perform the “interfascial” injection in all patients 
involved in our trials. 
Endpoints in the first trial (MH vs. PS)
 Regarding the primary endpoint, the mean NRS 
score in maximum pain related to motion decreased 
significantly “after the treatment” compared to 
“before the treatment” during the entire observation 
in both the PS and MH groups (p < 0.01). The PS 
group showed significantly lower NRS scores 
compared to the MH group (adjusted whole group 
difference; p < 0.05). Although there was no 
statistical difference between the groups until 9 hrs 
after injection, decreases in the NRS score in the PS 
group were significantly greater than in the MH 
group from 10 through 72 hrs after injection; from 10 
to 12 hrs after injection (p < 0.05), and from 24 to 72 
hrs after injection (p < 0.01)(Fig. 3a). 
 Concerning 4 secondary endpoints, the PS group 
showed a significantly longer lasting time of pain 
relief (p < 0.01)(Fig. 3b) compared to MH. The PS 
group showed greater intensity (p < 0.05)(Fig. 3c) and 
duration (p < 0.01)(Fig. 3d) of pain related to injection 
compared to the MH group. The passive ROM of the 
MPS affected muscle after the injection improved in 
both groups (20/20 in the PS group, 21/21 in the MH 
group). No serious adverse reactions were observed. 
Mild reactions after the injection (heavy feeling 
around the injection area) were reported by 2 patients 
Fig. 3. Results of the first trial.
 (a) The time course of the NRS score in the maximum pain related to motion (the primary endpoint) in the first trial. MH: (??◆??). PS 
(—□—). Data are presented as mean ? SEM. ?p < 0.05, ??p < 0.01. (b) Time of pain relief (hr). (c) Pain related to injection (pain intensity 
(NRS)). (d) Pain related to injection (pain duration (minute)). Data are presented as box (median ? interquartile (IQR)) and whiskers 
(10 and 90 percentile values). o: outliers. PS: physiological saline. MH: 0.5% mepivacaine hydrochloride. 
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in the PS group, and by 3 patients in the MH group. 
 To confirm that participants were kept blind until 
the study had finished, they were asked whether they 
knew the group to which they were assigned after 
turning in the records of the first trial. The answers of 
PS-injected patients (n = 20) were as follows. Four 
patients answered “PS”, 2 patients answered “MH”, 
and 14 patients answered “unknown”. The answers 
of MH-injected patients (n = 21) were as follows. 
Eight patients answered “PS”, 5 patients answered 
“MH”, and 8 patients answered “unknown”. The 
percentage of correct answer was 22% (9/41, 95% 
confidence interval 13-35%). The percentage of 
“unknown” was 54% (22/41, 38-69%). The results 
suggested that participants of the first trial were 
indicated to be blinded throughout the trial.
Endpoints in the second trial (BRS vs. PS)
 Regarding primary endpoints, the mean NRS 
score of maximum pain related to motion decreased 
significantly “after the treatment” compared to 
“before the treatment” in both the BRS and PS 
groups (p < 0.01). However, the time courses of the 
NRS scores were not statistically different between 
the BRS group and the PS group (p = 0.33)(Fig. 4a). 
 Concerning 4 secondary endpoints, there was no 
difference in the time of pain relief between the groups 
(p = 0.84)(Fig. 4b). The BRS group showed less 
intensity (p = 0.05)(Fig. 4c) and duration (p < 0.01)
(Fig. 4d) of pain related to injection than the PS group. 
The passive ROM of the MPS affected muscle after 
the injection improved in both groups (20/20 in the PS 
group, 21/21 in the BRS group). No serious adverse 
reactions were observed. Mild reactions after the 
Fig. 4. Results of the second trial.
 (a) The time course of the NRS score in the maximum pain related to motion (the primary endpoint) in the second trial. PS (??◆??). BRS 
(—□—). Data are presented as mean ? SEM. (b) Time of pain relief (hr). (c) Pain related to injection (pain intensity (NRS)). (d) Pain 
related to injection (pain duration (minute)). Data are presented as box (median ? interquartile (IQR)) and whiskers (10 and 90 
percentile values). o: outliers. BRS: bicarbonate Ringer’s solution. PS: physiological saline.
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injection (heavy feeling around the injection area) 
were reported by a patient in the PS group, but not in 
the BRS group. 
DISCUSSION
 The present studies indicated that interfascial 
injection of PS provided MPS patients with a longer 
analgesic effect and more pain related to injection 
than MH. In addition, BRS was equivalent to PS in 
analgesic effect and less problematic than PS in pain 
related to injection. The interfascial injection of BRS 
can thus be recommended as a more effective, and 
less painful local treatment for MPS patients. 
Study design and limitations
 Our study had 4 limitations. First, we chose to 
conduct 2 rounds of two-armed studies instead of one 
round of a three-armed trial. A three-armed trial 
would have required 75 patients. We sized up the 
situation that the maximum number of MPS patients 
was approximately 40 in a week when we could 
conduct one trial. We were concerned that symptoms 
and responses to our injections of the patients would 
be influenced by various factors including weather if 
more than one trial was conducted in different 
seasons. Symptoms of patients with chronic pain 
were influenced by bad weather and oncoming bad 
weather21)22). Second, we examined the short-term 
outcomes of a one-time approach to chronic pain 
(MPS) in our trials. Seventy-two hrs was considered 
to be the longest observation period possible that 
would not ethically interfere with the patients’ usual 
treatments, since we treat MPS patients twice a week 
when needed. Systematic reviews have shown that a 
one-time treatment of chronic pain does not result in 
long-term effects23)24). Irinich indicated the possible 
longer-lasting benefit of acupuncture, which might 
have action mechanisms similar to interfascial 
injection of BRS18). In the future, we should evaluate 
the long-term effects (beyond 72 hrs) and the effects 
of repeated interfascial injections of BRS. Third, 
although 6 patients were overlapped between the first 
trial (from January 26th to February 2nd 2013) and the 
second (from March 11th to 16th 2013), we did not 
consider it a problem because we performed the 
second trial more than a month after the first trial. 
Finally, the difference in the maximum pain related 
to motion between “before” and “after the injection” 
might have been affected by the placebo effects (e.g., 
the use of ultrasonography as a high-tech device, the 
expectation for the therapeutic procedure in the 
clinical study), and confounding factor (e.g. repeat 
measurement of maximum pain related to motion is 
associated with stretching, one of the therapies for 
MPS.). We used NRS as pain intensity scale instead 
of visual analogue scale (VAS) for the assessment of 
the maximum pain related to motion, although the 
assessment of pain in motion by NRS was rarely 
reported. Because, NRS has been shown to be as 
much sensitive as the VAS, and is preferred over 
VAS by patients for its relative simplicity and ease of 
administration and scaling25).
Choice of solutions
 The Cochrane Database showed that adjusting the 
pH of a solution to a level closer to the physiologic pH 
7.4 reduces pain related to injection9). Commercially 
available PS usually has a pH around 5.5 but can be as 
low as 4.626). Commercially available MH can have a 
variable pH (between 4.5 and 6.8). In the first trial, 
we chose the MH (pH 6.0, osmotic pressure 1.1 to 
PS; AstraZeneca plc, London, United Kingdom) as 
the local anesthetic, and the PS (pH 6.0; Otsuka 
Pharmaceutical Co., Ltd., Tokyo, Japan), because 
both have a pH and osmotic pressure very similar to 
each other and have been widely used for local 
injection in Japan. In the second trial, we chose 
BICANATE® (pH 7.4, osmotic pressure 0.9 to PS, 
Mg2+ 2 mEq/L; Otsuka Pharmaceutical Co., Ltd., 
Tokyo, Japan) as BRS, because BICANATE® has the 
pH most similar to blood plasma (pH 7.4) available 
in Japan. 
Choice of injection points
 Although the interfascial space with thick nerves 
(e.g., brachial plexus, axillary nerve, dorsal scapular 
nerve) running was presumed to be an effective 
space for performing the interfascial injections of a 
non-anesthetic agent, this space was not selected for 
our trials because the injection of a local anesthetic 
may cause hypoesthesia or paralysis. Therefore, we 
chose the 4 interfascial spaces so as not to let the 
participants know to which group they were 
assigned.
Pathophysiology of MPS
 The pathophysiology of MPS has not been fully 
understood. Some hypotheses have been proposed 27-29). 
More recently, myofascial trigger points have been 
considered as sites where nociceptors, such as 
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polymodal-type receptors, are sensitized by various 
factors (e.g., chemical, thermal, and mechanical 
stimulations)30)-32). In the myofascial trigger points 
compared to a normal muscle tissue, pH was low 
and the concentration of algesic substances (e.g., 
substance P and bradykinin) was high33). Low pH 
might contribute to the pathogenesis of peripheral 
hypersensitivity in chronic muscle pain via activating 
acid-sensing ion channels34). In addition, the 
viscoelasticity of myofascia was reported to modify 
activation of the neuronal transducers (e.g. , 
mechanoreceptors respond to surrounding tissue 
viscoelasticity) within myofascia35). Peripheral afferent 
in a muscle was responding to noxious stimuli to 
the myofascia16)36). Accordingly, we speculated that 
low pH, algesic substances, and mechanoreceptors 
in the interfascial space might be involved in the 
pathophysiology of MPS.
Possible action mechanism of interfascial injection 
for MPS
 Little is known about the action mechanism of 
interfascial injection on MPS. We speculated the 
following mechanisms of interfascial injection by 
MH, PS and BRS: 1) Na channel block by a local 
anesthetic; 2) acid stimuli by injection of low pH 
solution; 3) puncture stimuli by needle injection 
(same as acupuncture); 4) mechanical stimuli to 
myofascia by solution injection; 5) washout of the 
various algesic substances in the interfascial space; 
6) decreasing of the viscosity of interfascial fluid by 
injected solution; and 7) separation of the myofascial 
layers which reduces muscular friction resulting in 
smooth movement.
 Our first trial indicated that Na channel block by 
a local anesthetic did not have any factor affecting 
the analgesic effect of the interfascial injection for 
MPS because PS was more effective than MH (a 
local anesthetic). The strong pain intensity on PS 
injection might be related to the low pH because the 
pH of the PS we used was about 6.0. 
 Some studies indicated that the stronger the 
intensity of pain related to injection, the greater its 
analgesic effect7)8). However, our second trial showed 
that the strong intensity of pain related to injection 
and/or acid stimuli was not a factor related to its 
analgesic effect, because BRS (pH 7.4 and similar 
osmotic pressure to PS) was as effective as PS (pH 
6.0). Therefore, we speculated in light of these 
considerations that the factors contributing to the 
analgesic effect of interfascial injection are themselves 
stimuli to mechanoreceptors by needle puncture, 
mechanical stimuli by solution injection, the washout 
of various algesic substances in interfascial space 
which might stimulate hypersensitive nociceptors, 
decrease of the viscosity of interfascial fluid, and/or 
the separation of the myofascial layers which reduces 
friction. These possible affecting factors associated 
with the injection might produce the analgesic effect 
on MPS via normalizing the physiological function 
of interfascial space. 
Conclusion
 This study examined the effects of interfascial 
injection of PS, MH and BRS on MPS. The results 
suggested that the interfascial injection of PS had a 
greater analgesic effect on MPS but produced 
stronger pain related to injection compared to MH. 
BRS was equivalent to PS in analgesic effect and 
produced less pain related to injection compared to 
PS. Thus BRS would be the appropriate solution by 
interfascial injection for local therapy to MPS patients. 
The benefits of BRS are as follows: 1) effective, 2) less 
pain related to injection, and 3) no anesthetic side-
effects . The act ion mechanisms may not be 
proportionate to the strong pain related to injection 
nor the pharmacological anesthetic effect.
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